Skip to main content
Bliss GVS Pharma Limited logo

Bliss GVS Pharma Limited — Investor Relations & Filings

Ticker · BLISSGVS ISIN · INE416D01022 LEI · 335800GXY3YCGGP7KJ45 BSE.NS Manufacturing
Open in API
Filings indexed 1,243 across all filing types
Latest filing 2024-05-02 Regulatory Filings
Country IN India
Listing BSE.NS BLISSGVS

About Bliss GVS Pharma Limited

https://blissgvs.com/

Bliss GVS Pharma Limited specializes in the development, manufacturing, and marketing of diverse pharmaceutical formulations. The company is a global leader in the production of suppositories and pessaries, maintaining an extensive portfolio within these specialized dosage forms. Its therapeutic focus includes anti-malarials, anti-fungals, anti-bacterials, anti-inflammatories, and gastrointestinal treatments. The organization operates state-of-the-art manufacturing facilities compliant with international quality standards, including WHO-GMP. With a strategic focus on emerging markets, the company distributes its range of prescription and over-the-counter products across Sub-Saharan Africa, Southeast Asia, and Latin America, leveraging a robust supply chain to provide accessible healthcare solutions.

Recent filings

Filing Released Lang Actions
Recommended Final Dividend of 50% i.e. 50 Paisa per equity share on the face value of Rs. 1/- each for the financial year ended March 31, 2024, subject to the approval of the shareholders ....
Regulatory Filings Classification · 95% confidence The document is a formal communication addressed to stock exchanges (NSE and BSE) reporting the outcome of a Board Meeting held on May 2, 2024. It includes multiple announcements such as approval of audited standalone and consolidated financial results for the quarter and year ended March 31, 2024, declaration of unmodified audit opinion, recommendation of final dividend, re-appointments of internal and secretarial auditors, re-appointments and appointments of directors, and scheduling of the 39th Annual General Meeting. The document references enclosures (Annexures) containing detailed financial results and audit reports but does not itself contain the full financial statements or audit reports. The document is essentially an announcement of the board meeting outcomes and related corporate actions, not the full annual report or audit report itself. It is also longer than 5,000 characters, so it is not a brief notice. Given these factors, the document fits best as a Regulatory Filing (RNS) because it is a regulatory announcement of board meeting outcomes including financial results and director appointments, but not the full reports themselves.
2024-05-02 English
Book Closure
Regulatory Filings Classification · 95% confidence The document is a formal communication addressed to stock exchanges regarding the book closure dates for the company's register of members. It specifies the period of book closure from July 19, 2024, to July 25, 2024, for the purpose of holding the 39th Annual General Meeting (AGM) and payment of the final dividend for the financial year ended March 31, 2024. The document does not contain any financial statements, detailed financial data, or management discussion. It is an announcement related to administrative and procedural matters ahead of the AGM and dividend payment. The document length is short (2231 characters) and it serves as an intimation or notice rather than a full report. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2024-05-02 English
Please find attached herewith Outcome of the Board Meeting held on May 02, 2024.
Regulatory Filings
2024-05-02 English
Dividend
Regulatory Filings Classification · 95% confidence The document is a formal communication addressed to stock exchanges (NSE and BSE) reporting the outcome of a Board Meeting held on May 2, 2024. It includes multiple announcements such as approval of audited standalone and consolidated financial results for the quarter and year ended March 31, 2024, declaration of unmodified audit opinion, recommendation of final dividend, re-appointments of internal and secretarial auditors, re-appointments and appointments of directors, and scheduling of the 39th Annual General Meeting. The document references enclosures (Annexures) containing detailed financial results and audit reports but does not itself contain the full financial statements or audit reports. The document is essentially an announcement of the Board Meeting outcomes and related corporate actions, including the financial results approval and dividend recommendation, rather than the full Annual Report or Audit Report itself. It is also longer than 5,000 characters, so it is not a brief notice. Given these factors, the document fits best as a Regulatory Filing (RNS) because it is a regulatory announcement of board meeting outcomes and financial results approval, not the full financial report or audit report itself.
2024-05-02 English
Financial Result Updates
Regulatory Filings
2024-05-02 English
We would like to inform you that, the Board Meeting of the Company was held today i.e. Thursday, May 02, 2024 at the registered office of the Company. In pursuant to Regulation 30 and Regulation ....
Regulatory Filings
2024-05-02 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.